AX-202(Arxx Therapeutics)

N/A

Report date: 2023/08/22 20:00:59

Base Information

Drug NameAX-202(Arxx Therapeutics)
Drug Alias NameAX-202
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProtein S100-A4 inhibitors
TargetsProtein S100-A4
Therapy Area/IndicationsPsoriasisScleroderma, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorwayUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesArxx Therapeutics AS
China Registration ClassN/A

Develop Information

Active CompaniesArxx Therapeutics AS
Inactive CompaniesN/A
Active IndicationsPsoriasisScleroderma, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A